Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

被引：6

作者：

Gurbuz, Mustafa ^{[1
]}

Kutlu, Yasin ^{[2
]}

Akkus, Erman ^{[3
]}

Koksoy, Elif Berna ^{[1
]}

Kose, Naziyet ^{[4
]}

Oven, Bala Basak ^{[5
]}

Uluc, Basak Oyan ^{[6
]}

Demiray, Atike Gokcen ^{[7
]}

Erdem, Dilek ^{[8
]}

Demir, Bilgin ^{[9
]}

Turhal, Nazim Serdar ^{[10
]}

Uskent, Necdet ^{[10
]}

Akbas, Sinem ^{[11
]}

Selcukbiricik, Fatih ^{[11
]}

Inal, Ali ^{[12
]}

Bilici, Ahmet ^{[2
]}

Olmez, Omer Fatih ^{[2
]}

Cabuk, Devrim ^{[13
]}

Unal, Caglar ^{[14
]}

Hizal, Mutlu ^{[15
]}

Sendur, Mehmet Ali Nahit ^{[15
]}

Korkmaz, Mustafa ^{[16
]}

Karadurmus, Nuri ^{[17
]}

Erturk, Ismail ^{[17
]}

Goksu, Sema Sezgin ^{[18
]}

Tatli, Ali Murat ^{[18
]}

Guven, Deniz Can ^{[19
]}

Kilickap, Saadettin ^{[20
]}

Paksoy, Nail ^{[21
]}

Aydiner, Adnan ^{[21
]}

Cinkir, Havva Yesil ^{[22
]}

Ozkul, Ozlem ^{[23
]}

Ozturk, Akin ^{[24
]}

Balli, Sevinc ^{[1
]}

Kemal, Yasemin ^{[8
]}

Erdogan, Atike Pinar ^{[25
]}

Er, Ozlem ^{[26
]}

Yumuk, Perran Fulden ^{[11
]}

Demirkazik, Ahmet ^{[1
]}

机构：

[1] Ankara Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

[2] Istanbul Medipol Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey

[3] Ankara Univ, Fac Med, Dept Internal Med, Ankara, Turkey

[4] Mem Ankara Hosp, Dept Med Oncol, Ankara, Turkey

[5] Bahcesehir Univ, Fac Med, Dept Med Oncol, Gortepe Med Pk Hosp, Istanbul, Turkey

[6] Acibadem Altunizade Hosp, Dept Med Oncol, Istanbul, Turkey

[7] Pamukkale Univ, Fac Med, Dept Med Oncol, Denizli, Turkey

[8] Samsun Med Pk Hosp, Dept Med Oncol, Samsun, Turkey

[9] Adnan Menderes Univ, Fac Med, Dept Med Oncol, Aydin, Turkey

[10] Anadolu Med Ctr, Dept Med Oncol, Kocaeli, Turkey

[11] Koc Univ Hosp, Dept Med Oncol, Istanbul, Turkey

[12] Mersin City Hosp, Dept Med Oncol, Mersin, Turkey

[13] Kocaeli Univ, Fac Med, Dept Med Oncol, Kocaeli, Turkey

[14] Gayrettepe Florence Nightingale Hosp, Dept Med Oncol, Istanbul, Turkey

[15] Yildirim Beyazit Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

[16] Necmettin Erbakan Univ, Meram Fac Med, Dept Med Oncol, Konya, Turkey

[17] Univ Hlth Sci, Gulhane Training & Res Hosp, Dept Med Oncol, Ankara, Turkey

[18] Akdeniz Univ, Fac Med, Dept Med Oncol, Antalya, Turkey

[19] Hacettepe Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

[20] Istinye Univ, Liv Ankara Hosp, Fac Med, Dept Med Oncol, Ankara, Turkey

[21] Istanbul Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey

[22] Gaziantep Univ, Fac Med, Dept Med Oncol, Gaziantep, Turkey

[23] Bagcilar Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey

[24] Sureyyapasa Chest Dis & Thorac Surg Training & Re, Dept Med Oncol, Istanbul, Turkey

[25] Manisa Celal Bayar Univ, Dept Med Oncol, Fac Med, Manisa, Turkey

[26] Maslak Acibadem Hosp, Dept Med Oncol, Istanbul, Turkey

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2022年 / 148卷 / 12期

关键词：

Atezolizumab; Small cell lung cancer; Immunotherapy; PD-L1; ETOPOSIDE; PLATINUM;

D O I：

10.1007/s00432-022-04087-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC. Methods This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis. Results A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1-8) and atezolizumab cycle was 7 (1-32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7-7.8), and 11.9 months (95%CI 11-12.7), respectively. The ORR was 61.9%. ECOG-PS (p = 0.002) and number of metastatic sites (p = 0.001) were associated with PFS and pack-year of smoking (p = 0.05), while ECOG-PS (p = 0.03) and number of metastatic sites (p = 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable. Conclusion This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC.

引用

页码：3547 / 3555

页数：9

共 50 条

[1] Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group
Mustafa Gürbüz
Yasin Kutlu
Erman Akkuş
Elif Berna Köksoy
Naziyet Köse
Bala Başak Öven
Başak Oyan Uluç
Atike Gökçen Demiray
Dilek Erdem
Bilgin Demir
Nazım Serdar Turhal
Necdet Üskent
Sinem Akbaş
Fatih Selçukbiricik
Ali İnal
Ahmet Bilici
Ömer Fatih Ölmez
Devrim Çabuk
Çağlar Ünal
Mutlu Hızal
Mehmet Ali Nahit Şendur
Mustafa Korkmaz
Nuri Karadurmuş
İsmail Ertürk
Sema Sezgin Göksu
Ali Murat Tatlı
Deniz Can Güven
Saadettin Kılıçkap
Nail Paksoy
Adnan Aydıner
Havva Yeşil Çınkır
Özlem Özkul
Akın Öztürk
Sevinç Ballı
Yasemin Kemal
Atike Pınar Erdoğan
Özlem Er
Perran Fulden Yumuk
Ahmet Demirkazık
Journal of Cancer Research and Clinical Oncology, 2022, 148 : 3547 - 3555
[2] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Horn, L.
Mansfield, A. S.
Szczesna, A.
Havel, L.
Krzakowski, M.
Hochmair, M. J.
Huemer, F.
Losonczy, G.
Johnson, M. L.
Nishio, M.
Reck, M.
Mok, T.
Lam, S.
Shames, D. S.
Liu, J.
Ding, B.
Lopez-Chavez, A.
Kabbinavar, F.
Lin, W.
Sandler, A.
Liu, S. V.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23): : 2220 - 2229
[3] Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer
Kim, Soo Han
Jo, Eun Jung
Mok, Jeongha
Lee, Kwangha
Kim, Ki Uk
Park, Hye-Kyung
Lee, Min Ki
Eom, Jung Seop
Kim, Mi-Hyun
KOREAN JOURNAL OF INTERNAL MEDICINE, 2023, 38 (02): : 218 - 225
[4] Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
Wang, Yingcheng
Rui, Mingjun
Yang, Lan
Wang, Xintian
Shang, Ye
Ma, Aixia
Li, Hongchao
FRONTIERS IN PUBLIC HEALTH, 2021, 9
[5] Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer
Zhang, Dou
Kong, Fanming
Gao, Fangfang
Li, Longhui
Liang, Yangyueying
Yu, Minghui
Zhao, Lu
Wang, Na
Jia, Yingjie
HELIYON, 2024, 10 (01)
[6] Comparison of Real-world Efficacy and Safety of Atezolizumab and Durvalumab in Combination With Chemotherapy for First-line Treatment of Extensive-stage Small-cell Lung Cancer
Igata, Fumiyasu
Inoue, Hiroyuki
Ikeda, Takato
Nakao, Akira
Ebi, Noriyuki
Fujita, Masaki
ANTICANCER RESEARCH, 2024, 44 (07) : 3175 - 3183
[7] First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
Lijuan Li
Dan Yang
Yanmei Min
Anyan Liao
Jing Zhao
Leilei Jiang
Xin Dong
Wei Deng
Huiming Yu
Rong Yu
Jun Zhao
Anhui Shi
BMC Cancer, 23
[8] Anlotinib Plus Standard Chemotherapy as First-line Treatment in Extensive-Stage Small Cell Lung Cancer Patients
Zhang, W.
Yang, H.
Kong, T.
Han, B.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S536 - S536
[9] Anlotinib plus standard chemotherapy as first-line treatment in extensive-stage small cell lung cancer patients
Zhang, W.
Yang, H.
Kong, T.
Han, B.
ANNALS OF ONCOLOGY, 2022, 33 : S1580 - S1580
[10] Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Gao, F.
Zhao, Y.
Li, X.
Li, Y.
Ma, T.
Li, Q.
Tang, X.
Han, X.
Yi, S.
ANNALS OF ONCOLOGY, 2023, 34 : S1069 - S1069

← 1 2 3 4 5 →